MARKET

HBIO

HBIO

Harvard
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.68
-0.10
-1.29%
After Hours: 7.68 0 0.00% 16:41 09/24 EDT
OPEN
7.75
PREV CLOSE
7.78
HIGH
7.75
LOW
7.55
VOLUME
155.14K
TURNOVER
--
52 WEEK HIGH
8.75
52 WEEK LOW
2.740
MARKET CAP
313.06M
P/E (TTM)
-108.1690
1D
5D
1M
3M
1Y
5Y
3 Medical Equipment Stocks Under $10 to Buy Now
StockNews.com · 09/17 10:41
Acuitas Investments, LLC Buys The Cato Corp, Meridian Bioscience Inc, Gatos Silver Inc, Sells ...
GuruFocus News · 08/25 13:38
Stocks That Hit 52-Week Highs On Friday
    During Friday's morning session, 137 companies made new 52-week highs.
Benzinga · 08/13 14:14
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
BRIEF-Harvard Bioscience - On Aug 6, Court, With Regard To County Of Suffolk 2017 Complaint, Issued Ruling In Co's Favor, Vacating Sanctions
reuters.com · 08/09 21:42
Harvard Bioscience (HBIO) Tops Q2 Earnings and Revenue Estimates
Zacks.com · 08/05 13:05
Harvard Bioscience Announces Second Quarter 2021 Financial Results
Strong double digit revenue growth, solid margin performance despite global supply chain disruptions
GlobeNewswire · 08/05 11:00
-- Earnings Flash (HBIO) HARVARD BIOSCIENCE Posts Q2 Revenue $29.2M, vs. Street Est of $28M
MT Newswires · 08/05 07:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HBIO. Analyze the recent business situations of Harvard through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HBIO stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 31.85M
% Owned: 78.15%
Shares Outstanding: 40.76M
TypeInstitutionsShares
Increased
35
2.56M
New
22
1.16M
Decreased
31
1.26M
Sold Out
10
889.62K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.19%
Healthcare Equipment & Supplies
-0.42%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Green
Chief Financial Officer
Michael Rossi
Chief Operating Officer
Kenneth Olson
Lead Director/Independent Director
Bertrand Loy
Independent Director
Katherine Eade
Independent Director
Alan Edrick
Independent Director
Thomas Loewald
No Data
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer, and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. The Company provides products that support research in six different classes of laboratory use, including molecular, cellular, tissue, organ, organisms, and clinical. The Company primarily sells its products under several brand names, including Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The Company’s customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs, and government researchers.

Webull offers kinds of Harvard Bioscience, Inc. stock information, including NASDAQ:HBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HBIO stock methods without spending real money on the virtual paper trading platform.